Lisanti Capital Growth LLC Purchases New Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Lisanti Capital Growth LLC purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, Holdings Channel.com reports. The fund purchased 109,435 shares of the company’s stock, valued at approximately $8,638,000. TransMedics Group accounts for about 2.0% of Lisanti Capital Growth LLC’s holdings, making the stock its 3rd largest position.

A number of other institutional investors and hedge funds also recently made changes to their positions in TMDX. M&T Bank Corp lifted its stake in TransMedics Group by 41.1% in the 4th quarter. M&T Bank Corp now owns 12,164 shares of the company’s stock valued at $960,000 after purchasing an additional 3,541 shares during the last quarter. Los Angeles Capital Management LLC increased its holdings in shares of TransMedics Group by 27.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 10,344 shares of the company’s stock worth $816,000 after acquiring an additional 2,219 shares during the last quarter. First Horizon Advisors Inc. increased its holdings in shares of TransMedics Group by 26.8% during the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after acquiring an additional 222 shares during the last quarter. Mach 1 Financial Group LLC bought a new stake in TransMedics Group in the 4th quarter valued at $446,000. Finally, Valmark Advisers Inc. acquired a new stake in TransMedics Group during the 4th quarter valued at $576,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Price Performance

TransMedics Group stock traded up $4.66 during mid-day trading on Monday, reaching $132.65. 1,072,966 shares of the company were exchanged, compared to its average volume of 769,031. The company has a fifty day simple moving average of $86.63 and a 200-day simple moving average of $77.97. The firm has a market cap of $4.34 billion, a PE ratio of -390.15 and a beta of 1.87. The company has a debt-to-equity ratio of 3.18, a current ratio of 9.72 and a quick ratio of 8.76. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $132.85.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. The company had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. TransMedics Group’s revenue was up 132.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.08) earnings per share. As a group, equities research analysts expect that TransMedics Group, Inc. will post 0.62 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In related news, Director Edward M. Basile sold 7,157 shares of the stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total transaction of $618,221.66. Following the sale, the director now owns 8,350 shares in the company, valued at approximately $721,273. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Tamer I. Khayal sold 63,260 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the completion of the sale, the insider now owns 9,792 shares of the company’s stock, valued at $1,062,823.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward M. Basile sold 7,157 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $86.38, for a total value of $618,221.66. Following the transaction, the director now owns 8,350 shares in the company, valued at $721,273. The disclosure for this sale can be found here. In the last 90 days, insiders sold 236,378 shares of company stock valued at $23,633,449. Company insiders own 7.00% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on TMDX. Oppenheimer upped their price objective on shares of TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. JPMorgan Chase & Co. increased their price target on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Piper Sandler restated an “overweight” rating and set a $120.00 price objective (up from $95.00) on shares of TransMedics Group in a research report on Wednesday, May 1st. Canaccord Genuity Group upped their target price on TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Finally, TD Cowen boosted their price target on TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.00.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.